Telix Completes Enrollment in Pivotal Japan Phase 3 for Prostate Cancer Imaging Agent
TLX sits 69% above its 52-week low of $6.28 on light trading volume (0.4× avg).
Summary
Telix finished enrolling 105 patients in its Japanese Phase 3 study of TLX591-Px (Illuccix) for prostate cancer imaging. The data will back a New Drug Application in Japan, one of the largest nuclear medicine markets. A Conditional Approval application is already under review by Japan's PMDA, which could speed the regulatory timeline. This follows recent positive FDA feedback on the ProstACT Global trial and the opening of a new Melbourne manufacturing facility, reinforcing Telix's global prostate cancer franchise momentum.
At the time of this announcement, TLX was trading at $10.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $6.28 to $16.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.